[go: up one dir, main page]

ES2163495T3 - Sistema de suministro oftalmico de liquido de liberacion sostenida. - Google Patents

Sistema de suministro oftalmico de liquido de liberacion sostenida.

Info

Publication number
ES2163495T3
ES2163495T3 ES95906463T ES95906463T ES2163495T3 ES 2163495 T3 ES2163495 T3 ES 2163495T3 ES 95906463 T ES95906463 T ES 95906463T ES 95906463 T ES95906463 T ES 95906463T ES 2163495 T3 ES2163495 T3 ES 2163495T3
Authority
ES
Spain
Prior art keywords
approximately
polymer
liquid
ophthalmic
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95906463T
Other languages
English (en)
Inventor
Shau-Fong Yen
Kenneth W Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2163495T3 publication Critical patent/ES2163495T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

SE DESCRIBE UN SISTEMA DE ADMINISTRACION DE UN LIQUIDO ACUOSO OFTALMICO POR LIBERACION CONTINUA Y UN METODO PARA PROPORCIONAR UNA LIBERACION LENTA Y CONTINUA DE AGENTES DE TRATAMIENTO OFTALMICO AL OJO DE UN MAMIFERO, QUE CONSISTE EN ADMINISTRAR AL OJO DE DICHO MAMIFERO UNA CANTIDAD EFICAZ DE UNA COMPOSICION FARMACEUTICA OFTALMICA ACUOSA HOMOGENEA, DE PH ENTRE APROXIMADAMENTE 3,0 Y 6,2, EN FORMA DE GOTAS, Y QUE CONTIENE UNA CONCENTRACION OFTALMICAMENTE EFICAZ DEL AGENTE DE TRATAMIENTO OFTALMICO MENCIONADO Y ENTRE APROXIMADAMENTE 0,05% Y 10%, POR PESO, DEL POLIMERO QUITOSAN. ESTE POLIMERO CONSTA BASICAMENTE DE (A) UNIDADES ENLAZADAS DE {BE}(1-4)-D-GLUCOSAMINA MONOMERICA Y (B) UNIDADES ENLAZADAS DE {BE}(1-4)-N-ACETIL-D-G LUCOSAMINA MONOMERICA, DISTRIBUIDAS ALEATORIAMENTE EN LA MOLECULA DEL POLIMERO. LAS PROPORCIONES NUMERICAS DE A Y B SON ENTRE 60 Y 99%, APROXIMADAMENTE, DE A Y ENTRE 1 Y 40%, APROXIMADAMENTE, DE B. LA VISCOSIDAD ES DE ENTRE APROXIMADAMENTE 3 Y 3000 CPS. EN ESTE METODO, AL CONTACTO CON EL PH MAS ALTO DEL LIQUIDO OCULAR, LA FORMULACION LIQUIDA SE CONVIERTE EN UN GEL DEL QUE SE LIBERA LENTAMENTE EL AGENTE DE TRATAMIENTO OFTALMICO DURANTE UN PERIODO PROLONGADO DE TIEMPO.
ES95906463T 1994-02-18 1995-02-09 Sistema de suministro oftalmico de liquido de liberacion sostenida. Expired - Lifetime ES2163495T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/198,924 US5422116A (en) 1994-02-18 1994-02-18 Liquid ophthalmic sustained release delivery system

Publications (1)

Publication Number Publication Date
ES2163495T3 true ES2163495T3 (es) 2002-02-01

Family

ID=22735469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95906463T Expired - Lifetime ES2163495T3 (es) 1994-02-18 1995-02-09 Sistema de suministro oftalmico de liquido de liberacion sostenida.

Country Status (21)

Country Link
US (1) US5422116A (es)
EP (1) EP0744938B1 (es)
JP (1) JP3720359B2 (es)
CN (1) CN1138530C (es)
AT (1) ATE205079T1 (es)
AU (1) AU704353B2 (es)
CA (1) CA2181715C (es)
CY (1) CY2314B1 (es)
DE (1) DE69522550T2 (es)
DK (1) DK0744938T3 (es)
ES (1) ES2163495T3 (es)
FI (1) FI117851B (es)
GR (1) GR3036884T3 (es)
IL (1) IL112674A (es)
MX (1) MX9603435A (es)
NO (1) NO313861B1 (es)
NZ (1) NZ278668A (es)
PT (1) PT744938E (es)
TW (1) TW317501B (es)
WO (1) WO1995022315A1 (es)
ZA (1) ZA951323B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
IL120317A (en) * 1995-06-06 2000-08-13 Bayer Ag Ciprofloxacin-hydrocortisone suspension
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
AU6742696A (en) * 1995-08-17 1997-03-12 Ciba-Geigy Ag Stabilized chitin derivative compounds
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
DE69940227D1 (de) * 1998-05-08 2009-02-12 Univ Miami Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea
US7288532B1 (en) * 1998-08-21 2007-10-30 The University Of Maryland Biotechnology Institute Modified chitosan polymers and enzymatic methods for the production thereof
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
PT1128809E (pt) * 1998-11-20 2005-04-29 Medidom Lab Formulacoes oftalmicas aquosas comprendendo quitosano
BR0014203A (pt) * 1999-09-24 2002-05-21 Alcon Inc Formulações de suspensão tópicas contendo ciprofloxacina e dexametasona
WO2001032181A2 (en) 1999-11-01 2001-05-10 Alcon Universal Ltd. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
DK1229940T3 (da) * 1999-11-15 2014-08-18 Piramal Healthcare Canada Ltd Temperaturstyret og ph-afhængig selvgelerende, vandig biopolymeropløsning
EP1237585B1 (en) * 1999-12-09 2003-06-18 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
KR100371092B1 (ko) * 1999-12-09 2003-02-05 주식회사대성미생물연구소 동물용 복합항균제 조성물
US6348508B1 (en) * 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US6716970B2 (en) 2000-04-21 2004-04-06 Adjuvant Pharmaceuticals, Llc Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
ES2195819T3 (es) * 2000-05-26 2003-12-16 Medidom Lab Formulaciones oftalmicas acuosas antibacterianas que contiene ofloxacino y chitosan.
WO2002000272A2 (en) * 2000-06-29 2002-01-03 Biosyntech Canada Inc. Composition and method for the repair and regeneration of cartilage and other tissues
ATE279927T1 (de) 2000-07-28 2004-11-15 Alcon Inc Pharmazeutische zusammensetzungen enthaltend tobramycin und xanthangummi
AU2002221370A1 (en) * 2000-11-15 2002-05-27 Bio Syntech Canada Inc Method for restoring a damaged or degenerated intervertebral disc
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AU2002316467A1 (en) * 2001-06-27 2003-03-03 Diversa Corporation Glycosylated kinamycins and methods of making and using them
ATA13842001A (de) * 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
CA2493083C (en) * 2002-07-16 2012-11-06 Bio Syntech Canada Inc. Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors
US20070172821A1 (en) * 2002-08-23 2007-07-26 Li-Qun Wu Assembly of chitosan onto an electrode surface
AU2003275289A1 (en) * 2002-09-26 2004-04-19 University Of Maryland Baltimore County Polysaccharide-based polymers and methods of making the same
US7790010B2 (en) * 2002-12-20 2010-09-07 University Of Maryland, College Park Spatially selective deposition of polysaccharide layer onto patterned template
TW200416046A (en) * 2002-12-23 2004-09-01 Alcon Inc Contact lens care compositions containing chitin derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
MXPA05007718A (es) * 2003-01-24 2005-09-30 Control Delivery Sys Inc Dispositivo de liberacion sostenida y metodo para la administracion ocular de inhibidores de anhidrasa carbonica.
US7883615B2 (en) * 2003-02-12 2011-02-08 University Of Maryland, College Park Controlled electrochemical deposition of polysaccharide films and hydrogels, and materials formed therefrom
MXPA05008913A (es) * 2003-02-21 2005-10-05 Sun Pharmaceutical Ind Ltd Formulacion oftalmica estable que contiene antibiotico y corticoesteroide.
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7125967B2 (en) * 2003-10-08 2006-10-24 Adjuvant Pharmaceuticals, Llc Water-soluble chitosan having low endotoxin concentration and methods for making and using the same
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7375404B2 (en) * 2003-12-05 2008-05-20 University Of Maryland Biotechnology Institute Fabrication and integration of polymeric bioMEMS
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
KR101080056B1 (ko) * 2004-12-01 2011-11-04 한국원자력연구원 체내 주사시 겔화 안정성이 개선된 방사성물질-키토산복합체용액 조성물 및 그 제조 방법
ATE397439T1 (de) * 2005-02-17 2008-06-15 Jordanian Pharmaceutical Mfg Zubereitung zur kontinuierlichen arzneimittelfreisetzung chitosan enthaltend
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
EP1945712A4 (en) * 2005-11-04 2013-05-01 Piramal Healthcare Canada Ltd BINDING OF AQUEOUS POLYELECTROLYTE SOLUTIONS BY THERMALLY INDUCED CHANGES IN THE IONIZATION CONDITION
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US20070154523A1 (en) * 2005-12-30 2007-07-05 Rick Lewis Controlled pupil dilation for diagnostic and treatment of visual anomalies
US7785624B2 (en) * 2006-03-02 2010-08-31 Inspire Pharmaceuticals, Inc. Pharmaceutical latrunculin formulations
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
CA2676919C (en) * 2007-01-31 2013-01-29 Allergan, Inc. Novel biomaterials for ocular drug delivery and a method for making and using same
WO2008109397A2 (en) * 2007-03-02 2008-09-12 Saint Simeon Lda Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
CN101780105B (zh) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 小牛血去蛋白提取物的滴眼液
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
WO2011018800A2 (en) 2009-08-13 2011-02-17 Fdc Limited A novel in-situ gel forming solution for ocular drug delivery
DE102010009475B4 (de) 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
US20120231072A1 (en) * 2011-03-11 2012-09-13 Chemisches Institut Schaefer Ag Thermo-responsive hydrogel compositions
EP4272743A3 (en) 2011-09-20 2024-07-10 Allergan, Inc. Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
KR20150032552A (ko) 2012-06-11 2015-03-26 매큐클리어 인코포레이션 치료 제제 및 치료 방법
WO2015055301A1 (en) * 2013-10-15 2015-04-23 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
TWI609701B (zh) * 2016-01-05 2018-01-01 國立交通大學 滴點式複合藥物凝膠及其製備方法
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
CN106511268A (zh) * 2017-01-22 2017-03-22 吉林省始祖生物波医学研究院有限公司 治疗眼病的溶液及其应用、眼贴及其制作方法
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
BR112020017661A2 (pt) * 2018-02-28 2020-12-22 Santen Pharmaceutical Co., Ltd. Composição oftálmica compreendendo diquafosol e polímero catiônico
US12042500B2 (en) * 2018-04-03 2024-07-23 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
MX2020011301A (es) 2018-04-24 2021-01-29 Allergan Inc Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares.
US11344507B2 (en) 2019-01-08 2022-05-31 Alumend, Llc Topical compositions containing low molecular weight chitosan derivatives
IT201900006104A1 (it) 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Metodo di preparazione di un prodotto a base di chitosano
CN111848835B (zh) * 2019-04-30 2023-02-03 苏州大学 含氟化合物修饰的壳聚糖在透皮给药制剂制备中的应用
TWI848171B (zh) * 2019-08-27 2024-07-11 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、及聚乙烯吡咯烷酮之水性眼科用組合物
CN114073670B (zh) * 2020-08-11 2023-02-24 武汉科福新药有限责任公司 马来酸噻吗洛尔凝胶滴眼液及其制备方法
AU2022212108A1 (en) * 2021-01-28 2023-08-17 Glaukos Corporation Formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
IT1190347B (it) * 1986-06-16 1988-02-16 Franco Conti Processo per la preparazione dell'n-dimetilchitosano e suoi impieghi farmacologici
JPS6471822A (en) * 1987-09-12 1989-03-16 Rohto Pharma Ophthalmic sustained release preparation
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
JPH0418022A (ja) * 1990-05-10 1992-01-22 Fujikawa Kk ピロキシカムの安定水溶液ならびにその製造法
JP2536806B2 (ja) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels

Also Published As

Publication number Publication date
CY2314B1 (en) 2003-11-14
FI963217A0 (fi) 1996-08-16
NO313861B1 (no) 2002-12-16
TW317501B (es) 1997-10-11
GR3036884T3 (en) 2002-01-31
EP0744938B1 (en) 2001-09-05
DE69522550T2 (de) 2002-05-02
NZ278668A (en) 1998-01-26
PT744938E (pt) 2001-12-28
JP3720359B2 (ja) 2005-11-24
FI117851B (fi) 2007-03-30
ZA951323B (en) 1995-08-18
IL112674A0 (en) 1995-05-26
JPH09509166A (ja) 1997-09-16
AU1464995A (en) 1995-09-04
MX9603435A (es) 1997-03-29
IL112674A (en) 1999-12-22
NO963431D0 (no) 1996-08-16
DK0744938T3 (da) 2001-12-31
CN1138530C (zh) 2004-02-18
CN1140988A (zh) 1997-01-22
CA2181715A1 (en) 1995-08-24
EP0744938A1 (en) 1996-12-04
WO1995022315A1 (en) 1995-08-24
CA2181715C (en) 2006-05-30
AU704353B2 (en) 1999-04-22
US5422116A (en) 1995-06-06
ATE205079T1 (de) 2001-09-15
DE69522550D1 (de) 2001-10-11
FI963217A7 (fi) 1996-08-16
NO963431L (no) 1996-10-09

Similar Documents

Publication Publication Date Title
ES2163495T3 (es) Sistema de suministro oftalmico de liquido de liberacion sostenida.
PT754032E (pt) Composicoes liquidas para difusao
ES2161874T3 (es) Composicion oftalmica con viscosidad reducida.
ES2055677T3 (es) Composicion para el tratamiento de la disfuncion erectil.
MX9401396A (es) Dispositivos distribuidores eclosionables osmoticos activados por el ph.
ATE418325T1 (de) Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon- acetonid und hyaluronsäure
ES2184306T3 (es) Soluciones de acondicionamiento para el cuidado de las lentes de contacto duras.
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
DE69523733D1 (de) Thermisch gelierende trägerstoffe zur arzneistoffabgabe, die zelluloseether enthalten
DK0495421T3 (da) Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
ES2067939T3 (es) Sistema de distribucion de un medicamento iontoforetico con un perfil de reparto de dos etapas.
MX9301821A (es) Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
RU2012101782A (ru) Водные фармацевтические композиции, содержащие комплексы боратполиол
ATE533511T1 (de) Flüssige polymerzusammensetzung zur vorbeugung und behandlung von krankheiten der mundhöhle
AR022879A1 (es) Metodo y aparato de lisis por ultrasonido con transductor bimodal
PE20011284A1 (es) Mezclas de polimeros hidrofilicos usadas para la terapia de las vacas durante el periodo esteril
ES2125696T3 (es) Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
DK0594770T3 (da) Oftalmologiske blandinger
ES2118824T3 (es) Composiciones oftalmicas a base de acido poliacrilico.
RU99100578A (ru) Способ лечения глазных болезней
GT198274988A (es) Complejos de carboxilatos alcoxilados -- compuestos anfote ros que presentan propiedades de formacion de espuma conve nientes y baja irritacion ocular
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 744938

Country of ref document: ES